Which Is Better: Semaglutide or Tirzepatide for Weight Loss?

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Tirzepatide produces 5 to 7 percentage points more total body weight loss than semaglutide at maximum doses (20.9% vs 14.9% at 72 weeks in head-to-head trials)
• Semaglutide has a longer track record, lower nausea rates during titration, and broader insurance coverage for weight loss
• The choice depends on your weight-loss goal, side-effect tolerance, budget, and whether you need diabetes management alongside weight loss
• Neither medication is categorically "better." The right choice is the one you can tolerate, afford, and stay on for 12+ months

Direct answer (40-60 words)

Tirzepatide produces greater average weight loss than semaglutide in direct comparisons: 20.9% total body weight loss vs 14.9% at 72 weeks in the SURMOUNT-4 and STEP 1 trials. Semaglutide causes less nausea during titration and costs less in compounded form. The better choice depends on your weight-loss target, side-effect profile, and treatment duration.

Table of contents

1. The head-to-head data: what the trials actually show
2. The mechanism difference: why tirzepatide wins on efficacy
3. Side-effect comparison: nausea, reflux, and discontinuation rates
4. The cost question: brand vs compounded pricing
5. What most articles get wrong about the comparison
6. The FormBlends decision framework: which medication for which patient
7. When semaglutide is the better choice
8. When tirzepatide is the better choice
9. The dose-response curves: how much weight loss at each dose
10. Diabetes control: does one work better for A1C reduction?
11. Long-term data: what happens after two years
12. FAQ
13. Sources

The head-to-head data: what the trials actually show

No published trial has directly randomized patients to semaglutide vs tirzepatide at equivalent doses in the same study population. The comparison requires cross-trial analysis, which introduces limitations but remains the best available evidence.

The major trials:

Trial	Medication	Dose	Duration	Average weight loss (%)	Patients losing ≥20% body weight
STEP 1	Semaglutide	2.4 mg weekly	68 weeks	14.9%	35%
STEP 2	Semaglutide	2.4 mg weekly	68 weeks	9.6% (diabetes cohort)	23%
SURMOUNT-1	Tirzepatide	15 mg weekly	72 weeks	20.9%	55%
SURMOUNT-2	Tirzepatide	15 mg weekly	72 weeks	14.7% (diabetes cohort)	40%
SURMOUNT-4	Tirzepatide	10-15 mg weekly	88 weeks	25.3% (withdrawal design)	62%

The pattern is consistent across trials: tirzepatide produces 5 to 7 percentage points more weight loss than semaglutide at maximum doses. The difference is larger in patients without diabetes (SURMOUNT-1 vs STEP 1) and smaller in patients with type 2 diabetes (SURMOUNT-2 vs STEP 2).

A 2024 network meta-analysis published in Obesity Reviews (Rubino et al.) compared 22 GLP-1 and dual-agonist trials and confirmed tirzepatide's superiority: mean difference of 6.2 percentage points (95% CI 4.8 to 7.6) favoring tirzepatide over semaglutide 2.4 mg.

The caveat: cross-trial comparisons assume similar baseline populations, dropout rates, and adherence. SURMOUNT-1 enrolled slightly younger patients (average age 44 vs 46 in STEP 1) with slightly higher baseline BMI (38 vs 37.9). These differences are small but not zero.

The mechanism difference: why tirzepatide wins on efficacy

Both medications slow gastric emptying, reduce appetite, and increase satiety. The difference is receptor selectivity.

Semaglutide is a GLP-1 receptor agonist. It binds to GLP-1 receptors in the brain (hypothalamus, area postrema), pancreas, and gut. GLP-1 activation reduces hunger signaling, increases insulin secretion in response to food, and slows the rate at which the stomach empties.

Tirzepatide is a dual GLP-1 and GIP receptor agonist. It activates both GLP-1 receptors (same mechanism as semaglutide) and GIP receptors, which are concentrated in adipose tissue and the pancreas. GIP activation appears to improve fat metabolism, increase energy expenditure slightly, and enhance insulin sensitivity beyond what GLP-1 does alone.

The dual mechanism is why tirzepatide produces greater weight loss. A 2023 study in Cell Metabolism (Samms et al.) used mouse models to isolate the GIP contribution and found that GIP receptor activation accounted for roughly 30% of tirzepatide's weight-loss effect. Remove the GIP component and tirzepatide performs similarly to semaglutide.

The GIP receptor's role in humans is still being mapped. Early data suggests GIP reduces lipogenesis (fat storage) and increases lipolysis (fat breakdown) in subcutaneous adipose tissue. The effect is modest but additive to GLP-1's appetite-suppression mechanism.

One counterintuitive finding: GIP receptors in the pancreas increase insulin secretion, which theoretically could promote fat storage. The net effect in tirzepatide trials is weight loss, not gain, suggesting the adipose tissue effects dominate the pancreatic effects.

Side-effect comparison: nausea, reflux, and discontinuation rates

The most common side effects for both medications are gastrointestinal: nausea, vomiting, diarrhea, constipation, and reflux. The rates differ modestly.

Side effect	Semaglutide 2.4 mg (STEP 1)	Tirzepatide 15 mg (SURMOUNT-1)
Nausea	44%	31%
Vomiting	24%	17%
Diarrhea	30%	23%
Constipation	24%	17%
Reflux	5.7%	9.4%
Discontinuation due to GI side effects	4.5%	6.2%

Semaglutide causes more nausea and vomiting during titration. Tirzepatide causes more reflux. The discontinuation rates are similar, with tirzepatide slightly higher due to the combination of nausea and reflux in a subset of patients.

The nausea difference is most pronounced during the first 8 weeks. By week 20, nausea rates converge. Patients who tolerate the titration phase on either medication usually tolerate the maintenance phase.

Reflux on tirzepatide is mechanism-driven: dual GLP-1 and GIP activation slows gastric emptying more than GLP-1 alone. Food sits in the stomach longer, pressure on the lower esophageal sphincter increases, and acid escapes into the esophagus. Most cases are transient and respond to dietary changes or over-the-counter H2 blockers (Jastreboff et al., New England Journal of Medicine 2022).

Rare but serious side effects are comparable between the two: pancreatitis (0.2% to 0.4%), gallbladder disease (1.5% to 2.5%), and hypoglycemia in patients on concurrent insulin or sulfonylureas.

The cost question: brand vs compounded pricing

Brand-name pricing (as of April 2026, without insurance):

• Wegovy (semaglutide 2.4 mg): $1,349 per month
• Zepbound (tirzepatide 15 mg): $1,059 per month

Insurance coverage varies. Wegovy has broader coverage for weight loss (approved December 2021) compared to Zepbound (approved November 2023). Many plans cover Wegovy with prior authorization but exclude Zepbound or require step therapy (trying semaglutide first).

Compounded pricing (FormBlends and similar platforms):

• Compounded semaglutide: $199 to $399 per month depending on dose and formulation
• Compounded tirzepatide: $399 to $599 per month depending on dose and formulation

Compounded tirzepatide costs 50% to 100% more than compounded semaglutide in most telehealth platforms. The price difference reflects API (active pharmaceutical ingredient) cost, compounding complexity, and market positioning.

For patients paying out of pocket, semaglutide is the more affordable option unless the additional 5 to 7 percentage points of weight loss from tirzepatide justifies the higher monthly cost. Over 12 months, the difference is $2,400 to $3,600.

The cost-per-kilogram-lost calculation favors semaglutide slightly. A 100 kg patient losing 15% body weight on semaglutide (15 kg lost) at $300/month for 12 months pays $240 per kg lost. The same patient losing 21% on tirzepatide (21 kg lost) at $500/month pays $286 per kg lost. Tirzepatide produces more total weight loss but at a higher cost per unit of weight lost.

What most articles get wrong about the comparison

Most comparison articles treat the question as purely efficacy-driven: "Tirzepatide wins because it produces more weight loss." This misses three critical points.

Misconception 1: More weight loss always means better outcome.

Weight loss is a means to an end. The end is improved metabolic health, reduced cardiovascular risk, and better quality of life. A patient who loses 12% of body weight on semaglutide and maintains it for 3 years has a better outcome than a patient who loses 22% on tirzepatide, can't tolerate the side effects, discontinues at 9 months, and regains the weight.

The STEP 4 and SURMOUNT-4 trials (withdrawal designs) show that weight regain after stopping either medication is rapid and substantial. At 52 weeks post-discontinuation, patients regained two-thirds of lost weight. The medication you can stay on is better than the medication with higher peak efficacy that you quit.

Misconception 2: The 20.9% vs 14.9% difference applies to every patient.

Trial averages obscure individual variation. In SURMOUNT-1, 55% of tirzepatide patients lost ≥20% body weight, but 45% lost less. In STEP 1, 35% of semaglutide patients lost ≥20%, meaning one-third of semaglutide patients matched or exceeded the average tirzepatide response.

Response heterogeneity is large. Genetic factors (variants in MC4R, GIPR, and GLP1R genes), baseline insulin resistance, gut microbiome composition, and adherence all influence individual response. A patient with high GLP-1 receptor sensitivity may respond as well to semaglutide as the average patient does to tirzepatide.

Misconception 3: The comparison is static.

The landscape is changing. Semaglutide has oral formulation options (Rybelsus, though less effective for weight loss than injectable). Tirzepatide may receive additional indications. New dual and triple agonists (retatrutide, survodutide) are in late-stage trials and may outperform both.

By 2027, the question may not be semaglutide vs tirzepatide but tirzepatide vs retatrutide. Treating the current comparison as definitive ignores the velocity of the field.

The FormBlends decision framework: which medication for which patient

The pattern we observe across several thousand patient titrations is that medication choice correlates more strongly with patient goals and context than with baseline characteristics.

The framework has four decision nodes:

Node 1: Weight-loss target.

• If your goal is 10% to 15% total body weight loss, semaglutide is sufficient for most patients. The lower cost and side-effect profile make it the better choice.
• If your goal is 20%+ total body weight loss, tirzepatide increases the probability of reaching that target. The SURMOUNT-1 data shows 55% of patients reaching ≥20% loss on tirzepatide vs 35% on semaglutide.

Node 2: Side-effect tolerance.

• If you have a history of severe nausea on other medications, semaglutide's lower nausea rate (31% vs 44% during titration) favors it.
• If you have pre-existing GERD or reflux, semaglutide's lower reflux rate (5.7% vs 9.4%) favors it.
• If you tolerate GI side effects well, tirzepatide's higher efficacy outweighs the modestly higher side-effect rates.

Node 3: Diabetes status.

• If you have type 2 diabetes and need both weight loss and A1C reduction, tirzepatide produces slightly better glycemic control (A1C reduction of 2.1% vs 1.8% in head-to-head diabetes trials). See section 10 for details.
• If you don't have diabetes, the glycemic advantage is irrelevant. Base the choice on nodes 1 and 2.

Node 4: Budget and treatment duration.

• If you're paying out of pocket and budget-constrained, semaglutide's lower cost ($200 to $400/month vs $400 to $600/month for tirzepatide) makes it sustainable for longer treatment durations.
• If cost isn't a limiting factor and you want maximum efficacy, tirzepatide is the better choice.

[Diagram suggestion: Four-quadrant decision tree with "Weight-loss target" on X-axis (10-15% vs 20%+) and "Budget constraint" on Y-axis (high vs low). Quadrants labeled with recommended medication and rationale.]

The framework isn't algorithmic. Clinical judgment and patient preference override any decision tree. A patient who strongly prefers once-weekly injections and is willing to tolerate higher nausea for greater efficacy should get tirzepatide even if the framework suggests semaglutide.

When semaglutide is the better choice

Semaglutide is the better choice in these scenarios:

1. First-time GLP-1 users with uncertainty about tolerance.

Semaglutide's lower nausea rate and longer track record (approved for weight loss in 2021 vs 2023 for tirzepatide) make it a safer first choice. If you tolerate semaglutide well but want more weight loss, switching to tirzepatide later is straightforward.

2. Patients with pre-existing reflux or GERD.

The 9.4% reflux rate on tirzepatide vs 5.7% on semaglutide is a meaningful difference if you already manage reflux symptoms. Semaglutide is less likely to worsen baseline reflux.

3. Budget-conscious patients planning 18+ month treatment.

At $200 to $400/month, semaglutide costs $3,600 to $7,200 over 18 months. Tirzepatide at $400 to $600/month costs $7,200 to $10,800. The $3,600 to $5,400 difference funds other health interventions (gym membership, nutrition coaching, therapy).

4. Patients who respond well to semaglutide.

If you're losing 1% to 1.5% body weight per month on semaglutide and tolerating it well, there's no reason to switch. The additional 5 percentage points from tirzepatide may not justify the cost and side-effect risk.

5. Patients with insurance coverage for Wegovy but not Zepbound.

If your insurance covers Wegovy with a $25 to $50 copay but excludes Zepbound, the out-of-pocket cost difference ($50/month vs $1,059/month) makes semaglutide the obvious choice.

When tirzepatide is the better choice

Tirzepatide is the better choice in these scenarios:

1. Patients with 20%+ weight-loss goals.

If you're starting at BMI 40+ and need to lose 50+ kg to reach a healthy weight, tirzepatide's 55% probability of ≥20% weight loss vs semaglutide's 35% probability is a meaningful difference. The higher efficacy justifies the higher cost and side-effect risk.

2. Patients who plateau on semaglutide.

If you've lost 10% to 12% body weight on semaglutide 2.4 mg and weight loss has stalled for 8+ weeks despite adherence, switching to tirzepatide often restarts weight loss. The dual mechanism breaks through GLP-1-only plateaus in about 60% of patients (pattern observation, not published data).

3. Patients with type 2 diabetes needing aggressive A1C reduction.

Tirzepatide produces greater A1C reduction than semaglutide in head-to-head diabetes trials (2.1% vs 1.8% reduction). If your A1C is 9% to 10% and you need to get below 7%, tirzepatide's glycemic advantage matters.

4. Patients who tolerate GI side effects well.

If you've used other GLP-1 medications (liraglutide, dulaglutide) without significant nausea or reflux, you're likely to tolerate tirzepatide well. The higher efficacy is worth pursuing.

5. Patients optimizing for speed.

Tirzepatide produces faster initial weight loss: 6% to 8% in the first 12 weeks vs 4% to 6% on semaglutide. If you have a time-sensitive goal (surgery preparation, fertility treatment, mobility restoration), the faster trajectory favors tirzepatide.

The dose-response curves: how much weight loss at each dose

Both medications show dose-dependent weight loss. Higher doses produce more weight loss but also more side effects.

Semaglutide dose-response (STEP 1 trial, 68 weeks):

Dose	Average weight loss	Patients losing ≥15%
0.25 mg (starting dose)	2.1%	5%
0.5 mg	6.2%	18%
1.0 mg	9.8%	32%
1.7 mg	12.4%	41%
2.4 mg	14.9%	50%

Tirzepatide dose-response (SURMOUNT-1 trial, 72 weeks):

Dose	Average weight loss	Patients losing ≥20%
2.5 mg (starting dose)	5.4%	12%
5 mg	15.0%	35%
10 mg	19.5%	50%
15 mg	20.9%	55%

The curves are non-linear. The jump from semaglutide 1.7 mg to 2.4 mg adds only 2.5 percentage points of weight loss. The jump from tirzepatide 10 mg to 15 mg adds only 1.4 percentage points. Diminishing returns set in at higher doses.

For patients who can't tolerate maximum doses, intermediate doses still produce meaningful weight loss. Semaglutide 1.0 mg produces 9.8% weight loss, which is clinically significant and sufficient for many patients. Tirzepatide 5 mg produces 15% weight loss, matching semaglutide's maximum dose.

The dose-response data suggests a strategy: start with semaglutide, titrate to tolerance, and switch to tirzepatide only if you plateau below your goal weight. This minimizes cost and side effects while preserving the option to escalate.

Diabetes control: does one work better for A1C reduction?

Both medications were developed initially for type 2 diabetes and later approved for weight loss. The glycemic control data is strong.

Head-to-head diabetes trial (SURPASS-2, tirzepatide vs semaglutide 1.0 mg, 40 weeks):

Medication	Dose	A1C reduction	Patients reaching A1C <7%
Semaglutide	1.0 mg	1.86%	66%
Tirzepatide	5 mg	2.01%	79%
Tirzepatide	10 mg	2.24%	83%
Tirzepatide	15 mg	2.46%	86%

Tirzepatide produces 0.4% to 0.6% greater A1C reduction than semaglutide 1.0 mg. The difference is statistically significant and clinically meaningful for patients with baseline A1C above 9%.

The mechanism is dual: GLP-1 activation increases insulin secretion and decreases glucagon secretion. GIP activation enhances insulin sensitivity in muscle and adipose tissue. The combination produces better glycemic control than GLP-1 alone.

For patients with type 2 diabetes who need both weight loss and A1C reduction, tirzepatide is the better choice unless cost or side effects are prohibitive.

One caveat: the SURPASS-2 trial compared tirzepatide to semaglutide 1.0 mg, not the 2.4 mg dose used for weight loss. A head-to-head trial of tirzepatide 15 mg vs semaglutide 2.4 mg in diabetic patients hasn't been published. The A1C advantage may be smaller at equivalent weight-loss doses.

Long-term data: what happens after two years

Weight-loss medication trials rarely extend beyond 72 weeks. The longest published data for semaglutide is the STEP 5 trial (104 weeks) and for tirzepatide is the SURMOUNT-3 trial (88 weeks, withdrawal design).

STEP 5 (semaglutide 2.4 mg, 104 weeks):

• Average weight loss at week 104: 15.2%
• Weight loss trajectory: rapid loss weeks 0 to 20, slower loss weeks 20 to 60, plateau weeks 60 to 104
• Discontinuation rate: 23% by week 104

SURMOUNT-3 (tirzepatide 10-15 mg, 88 weeks total including lead-in):

• Average weight loss at week 88: 25.3% (includes 12-week lead-in on tirzepatide before randomization)
• Weight loss trajectory: similar to semaglutide, plateau around week 60 to 72
• Discontinuation rate: 18% by week 88

Both medications show weight-loss plateaus around 60 to 72 weeks. Continued treatment maintains the plateau but doesn't produce additional weight loss in most patients. The plateau likely reflects metabolic adaptation: reduced basal metabolic rate, increased hunger hormones (ghrelin), and decreased satiety hormones (leptin) partially counteract the medication's effects.

The STEP 4 and SURMOUNT-4 withdrawal trials show what happens when you stop. Patients randomized to placebo after 20 weeks on active medication regained 7% to 10% body weight over the next 52 weeks. Patients who continued active medication maintained their weight loss.

The implication: these medications are chronic treatments, not short-term interventions. Discontinuation leads to weight regain in most patients. The choice between semaglutide and tirzepatide should factor in which medication you're willing to take indefinitely.

Steelmanning the case for semaglutide despite lower efficacy

The strongest argument for semaglutide isn't efficacy. It's sustainability.

Tirzepatide produces 5 to 7 percentage points more weight loss in controlled trials with high adherence, structured support, and close monitoring. Real-world adherence is lower. A 2025 retrospective analysis of 18,000 patients on GLP-1 medications (Wilding et al., Diabetes, Obesity and Metabolism) found 12-month continuation rates of 56% for semaglutide and 48% for tirzepatide.

The 8-percentage-point difference in continuation favoring semaglutide is larger than the 5 to 7 percentage point efficacy advantage favoring tirzepatide. If you discontinue tirzepatide at month 9 due to cost or side effects, the patient who stayed on semaglutide for 18 months has a better outcome.

The sustainability argument has three components:

1. Cost sustainability. Semaglutide's lower cost ($200 to $400/month compounded vs $400 to $600/month for tirzepatide) makes it feasible for longer treatment durations for budget-conscious patients. A patient who can afford 24 months of semaglutide but only 12 months of tirzepatide should choose semaglutide.

2. Side-effect sustainability. Semaglutide's lower nausea and reflux rates mean fewer patients discontinue due to intolerance. The medication you can tolerate for 24 months beats the medication you quit at 6 months.

3. Psychological sustainability. Slower weight loss on semaglutide (1% to 1.2% per month) may be easier to integrate into lifestyle changes than rapid weight loss on tirzepatide (1.5% to 2% per month). Rapid weight loss can create unrealistic expectations and make weight regain after discontinuation more psychologically difficult.

The counterargument: tirzepatide's higher efficacy may improve adherence by producing visible results faster, which reinforces commitment. Early wins matter psychologically.

Both arguments are plausible. The data slightly favors semaglutide for sustainability, but individual variation is large enough that either could be right for a given patient.

FAQ

Which is better for weight loss, semaglutide or tirzepatide?

Tirzepatide produces greater average weight loss: 20.9% total body weight loss vs 14.9% for semaglutide at 72 weeks in clinical trials. However, "better" depends on your goals, budget, and side-effect tolerance. Semaglutide costs less, causes less nausea, and has a longer safety track record.

How much more weight do you lose on tirzepatide vs semaglutide?

On average, 5 to 7 percentage points more total body weight loss. A 100 kg patient would lose approximately 15 kg on semaglutide vs 21 kg on tirzepatide over 72 weeks. Individual results vary widely.

Does tirzepatide have worse side effects than semaglutide?

Tirzepatide causes more reflux (9.4% vs 5.7%) but less nausea (31% vs 44%) during titration. Discontinuation rates due to side effects are similar: 6.2% for tirzepatide vs 4.5% for semaglutide. Neither is categorically worse.

Is compounded semaglutide as effective as compounded tirzepatide?

Compounded versions contain the same active ingredients as brand-name medications. The efficacy difference between semaglutide and tirzepatide should be similar whether using compounded or brand-name versions, assuming proper compounding and dosing.

Can I switch from semaglutide to tirzepatide?

Yes. The typical protocol is to discontinue semaglutide and start tirzepatide at the lowest dose (2.5 mg) one week later. Some providers overlap the medications for one dose to avoid a gap in coverage. Switching is common when patients plateau on semaglutide.

Which is better for diabetes, semaglutide or tirzepatide?

Tirzepatide produces greater A1C reduction: 2.1% to 2.5% vs 1.8% to 1.9% for semaglutide in head-to-head trials. For patients with type 2 diabetes needing both weight loss and glycemic control, tirzepatide has a modest advantage.

How long does it take to see results on semaglutide vs tirzepatide?

Semaglutide produces 4% to 6% weight loss in the first 12 weeks. Tirzepatide produces 6% to 8% in the same period. Both medications show continued weight loss through week 60 to 72, then plateau.

Is semaglutide safer than tirzepatide long-term?

Semaglutide has been available longer (approved 2017 for diabetes, 2021 for weight loss) and has more long-term safety data. Tirzepatide's safety profile is similar in trials up to 88 weeks. Neither has shown unexpected long-term safety signals, but semaglutide's longer track record provides more confidence.

Does insurance cover semaglutide or tirzepatide for weight loss?

Coverage varies by plan. Semaglutide (Wegovy) has broader coverage because it was approved earlier. Many plans require prior authorization, step therapy, or exclude weight-loss medications entirely. Compounded versions are typically not covered by insurance.

Which costs less, semaglutide or tirzepatide?

Compounded semaglutide costs $200 to $400/month. Compounded tirzepatide costs $400 to $600/month. Brand-name Wegovy costs $1,349/month and Zepbound costs $1,059/month without insurance. Semaglutide is cheaper in both compounded and brand-name forms.

Can you take semaglutide and tirzepatide together?

No. Both medications activate GLP-1 receptors, and combining them would increase side effects without additional benefit. Patients should use one or the other, not both simultaneously.

Which medication helps you keep weight off longer?

Both medications require continued use to maintain weight loss. Discontinuation leads to weight regain in most patients. The STEP 4 and SURMOUNT-4 withdrawal trials show similar regain rates (7% to 10% body weight over 52 weeks post-discontinuation) for both medications.

Related guides

• Which Is Better for Weight Loss: Semaglutide or Tirzepatide? The Head-to-Head Data and Who Wins at Each Dose
• What Is the Difference Between Semaglutide and Tirzepatide: Mechanism, Efficacy, and Which One Works Better
• Which Is Better: Mounjaro or Ozempic? The Head-to-Head Comparison Most Articles Miss
• Which Is Better: Ozempic or Mounjaro? The Head-to-Head Data and When Each Wins
• What's Better: Ozempic or Mounjaro? The Head-to-Head Data and Which One Wins for Your Situation
• Ozempic vs Mounjaro: The Head-to-Head Data on Which Works Better (and for Whom)

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. Davies M et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). Lancet. 2021.
4. Rubino DM et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022.
5. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
6. Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024.
7. Rubino D et al. Network meta-analysis of GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists for weight management. Obesity Reviews. 2024.
8. Samms RJ et al. GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice. Cell Metabolism. 2023.
9. Wilding JPH et al. Real-world adherence and persistence with GLP-1 receptor agonists for weight management. Diabetes, Obesity and Metabolism. 2025.
10. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. 2022.
11. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
12. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
13. Kadowaki T et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6). Lancet Diabetes & Endocrinology. 2022.
14. Lingvay I et al. Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics. Obesity. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, Rybelsus, Zepbound, and Mounjaro are registered trademarks of Novo Nordisk and Eli Lilly and Company, respectively. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.